# Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

> **NCT03515369** · PHASE4 · UNKNOWN · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 459 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Tumor Recurrence

## Interventions

- **DRUG:** Babaodan oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03515369
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05
- **Primary completion:** 2022-01
- **Final completion:** 2022-06
- **Target enrollment:** 459 (ESTIMATED)
- **Last updated:** 2018-05-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515369, "Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03515369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*